HSP90AB1 and neoplasm: In an H1975 NSCLC xenograft model, CUDC-305 inhibited subcutaneous tumor growth and promoted degradation of multiple Hsp90 client proteins, such as mutant EGFR and key regulators of the RAF/MEK/ERK and PI3K/AKT signaling pathways (Figure 2) [187].